Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$591.74 +2.8%	$565.45	$471.97 ▼ $678.21	$35.22B	0.37	425,255 shs	377,872 shs
GSK GSK	$38.21 +0.5%	$39.02	$31.72 ▼ $44.67	$77.86B	0.5	5.82 million shs	4.73 million shs
INSM Insmed	$103.52 +0.1%	$89.86	$60.40 ▼ $106.83	$19.62B	0.9	4.17 million shs	1.64 million shs
TAK Takeda Pharmaceutical	$14.66 -0.6%	$14.89	$12.80 ▼ $15.53	$46.90B	0.23	2.81 million shs	4.30 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.73%	-0.43%	+6.41%	-4.18%	+21.69%
GSK GSK	+2.81%	-0.57%	-0.56%	+1.48%	-2.05%
INSM Insmed	+0.51%	-1.10%	-1.88%	+50.00%	+36.12%
TAK Takeda Pharmaceutical	+1.31%	+0.20%	+0.17%	-2.54%	+7.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	3.7289 of 5 stars	3.5	3.0	0.0	0.0	2.5	1.7	2.5
GSK GSK	1.7832 of 5 stars	1.1	3.0	2.5	0.0	1.8	0.0	2.5
INSM Insmed	4.0666 of 5 stars	2.5	4.0	0.0	4.3	3.4	1.7	0.6
TAK Takeda Pharmaceutical	2.1038 of 5 stars	0.0	5.0	2.5	0.0	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.10	Buy	$728.06	23.04% Upside
GSK GSK	2.11	Hold	$37.38	-2.20% Downside
INSM Insmed	3.00	Buy	$109.20	5.49% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest INSM, GSK, TAK, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$119.00 ➝ $130.00
7/21/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$715.00
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/8/2025	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
7/3/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$700.00
7/1/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/24/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/11/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	16.08	$3.05 per share	193.71	$90.49 per share	6.54
GSK GSK	$40.10B	1.95	$5.60 per share	6.82	$8.07 per share	4.74
INSM Insmed	$363.71M	54.00	N/A	N/A	$1.60 per share	64.70
TAK Takeda Pharmaceutical	$30.09B	1.55	$3.16 per share	4.64	$14.39 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	36.50	54.54	1.00	40.20%	16.15%	14.33%	7/31/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.70	8.22	1.55	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	66.62	8.88	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest INSM, GSK, TAK, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	N/A	N/A
7/31/2025	Q2 2025	ARGX argenex	$2.87	N/A	N/A	N/A	$776.82 million	N/A
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.71	4.47%	N/A	88.14%	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.75%	N/A	250.00%	N/A

Latest INSM, GSK, TAK, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
GSK GSK	1.21	0.87	0.58
INSM Insmed	11.38	5.86	5.44
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
GSK GSK	15.74%
INSM Insmed	N/A
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
GSK GSK	10.00%
INSM Insmed	3.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

INSM, GSK, TAK, and ARGX Headlines

Recent News About These Companies

Pregnancy Incidence Among Isotretinoin Users May Be Affected by Race, Insurance Type

July 24 at 5:28 AM | medscape.comM

Takeda appoints Hernán Porcile as Head of the EAMEA region, continuing its legacy of visionary leadership

July 24 at 5:28 AM | zawya.comZ

Takeda Pharmaceutical (TAK) Expected to Announce Quarterly Earnings on Wednesday

July 23 at 8:06 AM | marketbeat.com

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Acquired by Cerity Partners LLC

July 20, 2025 | marketbeat.com

Envestnet Asset Management Inc. Has $13.25 Million Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

July 19, 2025 | marketbeat.com

IDSA Updates Guidelines on Complicated UTIs

July 18, 2025 | medscape.comM

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

July 17, 2025 | seekingalpha.com

Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton

July 15, 2025 | tipranks.com

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in ...

July 14, 2025 | gurufocus.com

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

July 14, 2025 | businesswire.com

Takeda: Positives And Negatives Offset Each Other

July 11, 2025 | seekingalpha.com

Vontobel Holding Ltd. Acquires New Shares in Takeda Pharmaceutical Co. (NYSE:TAK)

July 9, 2025 | marketbeat.com

Crossmark Global Holdings Inc. Purchases 186,349 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

July 8, 2025 | marketbeat.com

Callan Capital LLC Invests $735,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

July 8, 2025 | marketbeat.com

Takeda Completes Treasury Share Disposal with Minor Adjustments

July 8, 2025 | tipranks.com

Lupin gets USFDA approval for post-eye surgery drug

July 2, 2025 | indiainfoline.comI

Takeda Pharmaceutical Co. (NYSE:TAK) Stock Position Raised by Sequoia Financial Advisors LLC

July 1, 2025 | marketbeat.com

FDA Approves Takeda’s Gammagard Liquid ERC

June 30, 2025 | contractpharma.comC

Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - What's Next?

June 30, 2025 | marketbeat.com

Sclerosing Mesenteritis: What GIs Need to Know About This Rare Disease

June 28, 2025 | medscape.comM

Herbosa cites Dengvaxia lesson as PH mulls approval of Qdenga vaccine

June 28, 2025 | gmanetwork.comG

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
By Leo Miller | July 2, 2025
View The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
3 Streaming Stocks to Watch as Subscribers Drive Growth
By Chris Markoch | July 20, 2025
View 3 Streaming Stocks to Watch as Subscribers Drive Growth
Super Micro Stock May Benefit as Cooling Demand Takes Off
By Gabriel Osorio-Mazilli | July 16, 2025
View Super Micro Stock May Benefit as Cooling Demand Takes Off

INSM, GSK, TAK, and ARGX Company Descriptions

argenex NASDAQ:ARGX

$591.74 +16.32 (+2.84%)

Closing price 04:00 PM Eastern

Extended Trading

$591.43 -0.31 (-0.05%)

As of 06:53 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

GSK NYSE:GSK

$38.21 +0.18 (+0.48%)

Closing price 03:59 PM Eastern

Extended Trading

$38.26 +0.05 (+0.12%)

As of 07:54 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Insmed NASDAQ:INSM

$103.52 +0.08 (+0.08%)

Closing price 04:00 PM Eastern

Extended Trading

$104.16 +0.64 (+0.61%)

As of 07:51 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Takeda Pharmaceutical NYSE:TAK

$14.66 -0.09 (-0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$14.70 +0.05 (+0.34%)

As of 07:37 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time